Ritter Pharmaceuticals (NASDAQ:RTTR) Getting Somewhat Positive News Coverage, Study Finds

Headlines about Ritter Pharmaceuticals (NASDAQ:RTTR) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ritter Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.5533164883819 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Shares of RTTR traded down $0.01 during midday trading on Friday, reaching $2.48. The company had a trading volume of 52,304 shares, compared to its average volume of 115,469. The company has a market capitalization of $12.30, a PE ratio of -0.50 and a beta of 0.58. Ritter Pharmaceuticals has a 1-year low of $1.80 and a 1-year high of $14.60.

How to Become a New Pot Stock Millionaire

Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings data on Monday, March 19th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.60). equities analysts expect that Ritter Pharmaceuticals will post -2.8 EPS for the current year.

A number of analysts have issued reports on RTTR shares. Zacks Investment Research downgraded Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, December 26th. ValuEngine raised Ritter Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $13.75.

COPYRIGHT VIOLATION NOTICE: “Ritter Pharmaceuticals (NASDAQ:RTTR) Getting Somewhat Positive News Coverage, Study Finds” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/ritter-pharmaceuticals-rttr-receives-media-impact-rating-of-0-14.html.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Insider Buying and Selling by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply